Brief: Protagonist Therapeutics Q4 EPS USD -0.69
25/02/2026 21:05
Feb 25 (Reuters) - Protagonist Therapeutics Q4 license and collaboration revenue USD 7.437 million. Q4 net income USD -44.384 million Q4 operating expenses USD 57.792 million
Recent news on Protagonist Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Adobe, Braveheart Bio, CACI International
US FDA approves Takeda, Protagonist's drug for rare blood cancer (updated)
US FDA approves Takeda, Protagonist's drug for rare blood cancer
Silence Therapeutics jumps after mid-stage trial data for blood cancer drug
Protagonist Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary